Latest News and Press Releases

Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Trading Update and Successful Litigation Settlement  2019 full year earnings expected to be ahead of market expectations 27 June...

Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Allergy Therapeutics Publishes New Research Exploring Potential of its Adjuvant Systems in the Treatment of Cancer in the Journal of...

Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”)  Trading update Group’s market share continues to grow 12 July 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated...

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in...

Allergy Therapeutics plc("Allergy Therapeutics", the “Group” or “Company") Positive new clinical data with house-dust mite immunotherapy ~ House-dust mite immunotherapy shown to be well-tolerated...

Allergy Therapeutics plc("Allergy Therapeutics" or the "Group")  Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary...

Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant,...

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0930 GMT...

Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 ...

Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Trading Update Market share gains driving top line growthStrong cash position sustained by good performance. 31 January 2017...